Concepedia

Debora Williams‐Herman

DW

Statistics

Publications

40

Citations

5.6K

H-Index

30

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Duke Medical Center

University of California, San Francisco

Charité - Universitätsmedizin Berlin

Asociación Colombiana de Diabetes

Debora Williams‐Herman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Publications per year

1994–2018

40

Publications

40

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Pablo Aschner, Mark Kipnes, Jared Lunceford et al. · Diabetes Care · 2006 · 881 citations

, , +17

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Itamar Raz, M Hanefeld, Lei Xu et al. · Diabetologia · 2006 · 617 citations · Full text

, , +13

Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency

Donald B. Kohn, Kenneth I. Weinberg, Jan A. Nolta et al. · Nature Medicine · 1995 · 611 citations · Full text

, , +15

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Jared Lunceford, Jeremy Johnson, Debora Williams‐Herman · Diabetes Care · 2007 · 490 citations · Full text

, , +17

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

Debora Williams‐Herman, Samuel S. Engel, Elizabeth Round et al. · BMC Endocrine Disorders · 2010 · 255 citations · Full text

, , +14

1–5 of 40